Compare Moderna, Inc. (MRNA) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Victoria's Secret & Co — how do they compare? Moderna, Inc. trades at $137.05 (market cap $56.02B), while Victoria's Secret & Co trades at $76 (market cap $6.26B). The key difference: Moderna, Inc. is far larger — about 8.9× Victoria's Secret & Co's market cap. Which is the better fit depends on your goals.
| MRNA | VSXY | |
|---|---|---|
Market Cap | $56.02B | $6.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $174.38 | $99.97 |
52-Week Low | $22.36 | $25.56 |
Enterprise Value | $52.17B | $8.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Victoria's Secret (VSXY) trades at $78.47, up 3.85% over 24 hours, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability metrics, including a 45.27% ROE and 39.57% gross margin, but faces revenue stagnation and negative net cash flow trends. Recent news highlights PINK brand growth and Q2 2026 earnings surpassing estimates, though the stock fell due to sales concerns.
The outlook is mixed: analyst consensus is bullish with a $94.86 price target, but technical weakness and competitive pressures pose risks. Earnings momentum and cost management are key drivers for upside, while investor sentiment remains cautious amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
